Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

Pietzner, Klaus; Woopen, Hannah; Richter, Rolf; Joens, Thomas; Braicu, Elena Ioana; Dimitrova, Desislava; Mellstedt, Håkan; Darb‐Esfahani, Silvia; Denkert, Carsten; Lindhofer, Horst; Fotopoulou, Christina; Sehouli, Jalid

doi:10.1097/igc.0b013e3182929056

Cited by 14 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the great majority of cancer entities, EpCAM overexpression strongly correlates with worse overall survival rate and poor prognosis [69], and distinguishes patients at high risk for recurrence [70]. However, in some entities such as pancreatic and gastrointestinal cancers, EpCAM overexpression correlates with better prognosis [55].…”

Section: Resultsmentioning

confidence: 99%

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Vitale

Laganà

Capriglione

et al. 2017

IJMS

View full text Add to dashboard Cite

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”, “angiogenesis therapy”, “cancer stem cell therapy”, “prognostic biomarker”, and “novel antibody-drug”. Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy. Nevertheless, future investigations are needed to clarify the impact of these new therapies on survival rate and medium-/long-term outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Vitale

Laganà

Capriglione

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…As such, CAMs may promote or suppress the metastatic potential of tumor cells [10]. Similar to other epithelial cancers, cell adhesion molecules must play a role in the progression of ovarian cancer, especially since aberrant expression of various CAMs, such as mucins [11], integrins [12], CD44 [13], L1CAM [14], cadherin [15], claudins [16], EpCAM [17], ALCAM [18] and METCAM/MUC18 [19,20], has been associated with the malignant progression of ovarian cancer. Some of the CAMs may play a positive role, such as MUC4 [21], CD44 [22], L1CAM [23], ALCAM [18], and P-cadherin [24]; however, some a negative role, such as β3-integrin [25], E-cadherin [26], claudin-3, 4, &7 [27], EpCAM [28], and KAI1 [29], in the progression of ovarian cancer cells.…”

Section: Cell Adhesion Molecules and The Progression Of Ovarian Cancermentioning

confidence: 99%

METCAM/MUC18 plays a Novel Tumor and Metastasis Suppressor Role in the Progression of Human Ovarian Cancer Cells

Wu¹

2017

OGIJ

View full text Add to dashboard Cite

METCAM/MUC18, an integral membrane cell adhesion molecule (CAM) in the Iglike gene super-family, is capable of performing typical functions of CAMs, such as mediating cell-cell and cell-extracellular interactions, crosstalk with intracellular signaling pathways, and modulating social behaviors of cells. The role of METCAM/ MUC18 in the progression of ovarian cancer cells has not been well studied. Previous studies showed that METCAM/MUC18 is expressed in normal ovarian epithelial cells, but expressed at higher levels in ovarian cancer tissues, suggesting that METCAM/ MUC18 may serve as a biomarker for the malignant progression of clinical ovarian cancers and it has been implicated for playing a positive role in the progression of the cancer. Recently we provided evidence from in vitro and in vivo studies to suggest that the above notion is a fortuitous correlation and that METCAM/MUC18 actually serves as a tumor and metastasis suppressor for the malignant progression of ovarian cancer cells, similar to its role in the malignant progression of one mouse melanoma cell line and nasopharyngeal carcinoma type I. Many possible mechanisms mediated by this CAM during early tumor development and metastasis are suggested. Furthermore, we suggest that METCAM/MUC18 may be used a therapeutic reagent to arrest the malignant progression of clinical ovarian cancer.

show abstract

“…EpCAM was reported to be exclusively present in epithelial tissues and is highly expressed across a large number of epithelial cancers (2)(3)(4)(5)(6)(7)(8)(9)(10)(11). Particular interest has been focused on EpCAM expression as a poor prognostic biomarker across a large number of carcinomas (2,(4)(5)(6)(8)(9)(10)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas

Ward

Amaya

Verma

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Epithelial cell adhesion molecule (EpCAM) is a protein involved in cell-to-cell attachment and is considered to be strictly expressed in epithelial tissues and epithelial-derived tumors. Furthermore, EpCAM has been shown to be a negative prognostic marker for several carcinomas. In this study, we performed a genomic meta-analysis of gene expression profiles housed in the Cancer Cell Line Encyclopedia to demonstrate that EpCAM mRNA is expressed at low to moderate levels in certain sarcoma cell lines. We utilized immunohistochemical staining to confirm that the EpCAM protein is expressed in a subset of angiosarcomas and leiomyosarcomas and in all the investigated osteosarcomas. Finally, we conducted a statistical analysis of clinical data to demonstrate that EpCAM protein expression is significantly and directly correlated with the degree of cytological atypia in leiomyosarcomas. In conclusion, this data suggests that, contrary to conventional beliefs, EpCAM is expressed in a subset of sarcomas and is a negative prognostic marker for leiomyosarcomas.

show abstract

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

Abstract: Epithelial cell adhesion molecule expression profile appears to remain stable during the course from the primary throughout the relapse of serous OC. The results indicate that EpCAM might be an interesting therapeutic target structure in serous OC.

Cited by 14 publications

References 20 publications

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

METCAM/MUC18 plays a Novel Tumor and Metastasis Suppressor Role in the Progression of Human Ovarian Cancer Cells

Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas

Contact Info

Product

Resources

About